- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05775159
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) and/or in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).
This study has a modular design with independent substudies. In Substudy 1, Volrustomig and Rilvegostomig will be evaluated as monotherapy and/or in combination with other anticancer drugs in approximately 200 evaluable participants with advanced HCC.
In Substudy 2, the efficacy and safety of Rilvegostomig or Volrustomig plus gemcitabine and cisplatin are investigated in approximately 60 evaluable participants with advanced BTC who have not received previous treatment for advanced/metastatic disease.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Beijing, China, 100050
- Recruiting
- Research Site
-
Beijing, China, 100142
- Recruiting
- Research Site
-
Beijing, China, 101100
- Recruiting
- Research Site
-
Chengdu, China, 610000
- Recruiting
- Research Site
-
Chengdu, China, 610041
- Recruiting
- Research Site
-
Chongqing, China, 400030
- Recruiting
- Research Site
-
Fuzhou, China, 350007
- Recruiting
- Research Site
-
Guangzhou, China, 510060
- Not yet recruiting
- Research Site
-
Guangzhou, China, 510515
- Recruiting
- Research Site
-
Harbin, China, 150081
- Recruiting
- Research Site
-
Hefei, China, 230601
- Not yet recruiting
- Research Site
-
Hefei, China, 230001
- Not yet recruiting
- Research Site
-
Hefei, China, 230022
- Recruiting
- Research Site
-
Nanchang, China, 330006
- Recruiting
- Research Site
-
Nanning, China, 530021
- Recruiting
- Research Site
-
Shandong, China
- Not yet recruiting
- Research Site
-
Shanghai, China, 200032
- Recruiting
- Research Site
-
Xi'an, China, 710038
- Not yet recruiting
- Research Site
-
Zhengzhou, China, 450008
- Withdrawn
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 150001
- Recruiting
- Research Site
-
Shatin, Hong Kong, 00000
- Recruiting
- Research Site
-
-
-
-
-
Firenze, Italy, 50134
- Recruiting
- Research Site
-
Milano, Italy, 20132
- Recruiting
- Research Site
-
Napoli, Italy, 80131
- Recruiting
- Research Site
-
Rozzano, Italy, 20089
- Recruiting
- Research Site
-
-
-
-
-
Chuo-ku, Japan, 104-0045
- Recruiting
- Research Site
-
Kashiwa, Japan, 277-8577
- Recruiting
- Research Site
-
Yokohama-shi, Japan, 241-8515
- Recruiting
- Research Site
-
-
-
-
-
Seongnam-Si, Korea, Republic of, 463-712
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Research Site
-
-
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Research Site
-
Barcelona, Spain, 8035
- Recruiting
- Research Site
-
Madrid, Spain, 28007
- Recruiting
- Research Site
-
Madrid, Spain, 28040
- Recruiting
- Research Site
-
Pamplona, Spain, 31008
- Recruiting
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 80756
- Recruiting
- Research Site
-
Kaohsiung city, Taiwan, 833
- Recruiting
- Research Site
-
Liuying, Taiwan, 736
- Recruiting
- Research Site
-
Taichung, Taiwan, 40705
- Recruiting
- Research Site
-
Tainan City, Taiwan, 70403
- Recruiting
- Research Site
-
Taipei, Taiwan, 10002
- Recruiting
- Research Site
-
Taipei, Taiwan, 11259
- Recruiting
- Research Site
-
Taoyuan, Taiwan, 333
- Recruiting
- Research Site
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Recruiting
- Research Site
-
Edinburgh, United Kingdom, EH4 2XU
- Withdrawn
- Research Site
-
London, United Kingdom, NW3 2QG
- Recruiting
- Research Site
-
Manchester, United Kingdom, M20 4BX
- Not yet recruiting
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Research Site
-
-
California
-
Costa Mesa, California, United States, 92627
- Recruiting
- Research Site
-
Orange, California, United States, 92868
- Recruiting
- Research Site
-
-
Florida
-
Miami Beach, Florida, United States, 33140
- Withdrawn
- Research Site
-
-
Indiana
-
Dyer, Indiana, United States, 46311
- Withdrawn
- Research Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- Recruiting
- Research Site
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75251
- Not yet recruiting
- Research Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Not yet recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years at the time of signing the ICF.
- Provision of a signed and dated written ICF.
- Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology.
- Adequate organ and bone marrow function.
- At least 1 measurable not previously irradiated lesion per RECIST 1.1
- Life expectancy of at least 12 weeks at the time of screening.
- Willing and able to provide an adequate tumor sample.
Exclusion Criteria:
- History of allogeneic organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders.
- Uncontrolled intercurrent illness.
- History of another primary malignancy, leptomeningeal carcinomatosis, and active primary immunodeficiency.
- Active infection, brain metastases or spinal cord compression.
- Participants co-infected with HBV and hepatitis D virus (HDV).
- Previous treatment in the present study.
- For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1A
Volrustomig monotherapy
|
CTLA-4/Anti-PD-1 Bispecific Antibody
|
Experimental: Cohort 1B
Volrustomig combination with bevacizumab
|
15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops.
CTLA-4/Anti-PD-1 Bispecific Antibody
|
Experimental: Cohort 1C
Volrustomig combination with lenvatinib
|
Daily use per oral (8 mg capsules/day for participants < 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops.
CTLA-4/Anti-PD-1 Bispecific Antibody
|
Experimental: Cohort 2A
Rilvegostomig combination with Gemcitabine and Cisplatin
|
1000 mg/m2, IV infusion
25 mg/m2, IV infusion
anti- PD-1 and TIGIT bispecific antibody
|
Experimental: Cohort 2B
Volrustomig combination with Gemcitabine and Cisplatin
|
1000 mg/m2, IV infusion
25 mg/m2, IV infusion
CTLA-4/Anti-PD-1 Bispecific Antibody
|
Experimental: Cohort 1D
Volrustomig combination with rilvegostomig and bevacizumab
|
15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops.
CTLA-4/Anti-PD-1 Bispecific Antibody
anti- PD-1 and TIGIT bispecific antibody
|
Experimental: Cohort 1E
Rilvegostomig combination with bevacizumab
|
15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle.
Number of Cycles: until disease progression or unacceptable toxicity develops.
anti- PD-1 and TIGIT bispecific antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of participants with adverse events/serious adverse events
Time Frame: Through study completion, an average of 2 years
|
Number of participants with adverse events and with serious adverse events including abnormal clinical observations, abnormal Electrocardiogram (ECG) parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline.
|
Through study completion, an average of 2 years
|
Objective response rate (ORR)
Time Frame: Through study completion, an average of 2 years
|
ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1 (For HCC sub-study 1)
|
Through study completion, an average of 2 years
|
Progression free survival (PFS)
Time Frame: Through study completion, an average of 2 years
|
PFS is defined as the time from the start of studyintervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression, whichever occurs first.
(For BTC sub-study 2)
|
Through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Through study completion, an average of 2 years
|
ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1
|
Through study completion, an average of 2 years
|
Duration Of Response (DOR)
Time Frame: Through study completion, an average of 2 years
|
DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 by the Investigator at local site or death due to any cause in the absence of disease progression, whichever occurs first.
|
Through study completion, an average of 2 years
|
Disease Control Rate (DCR)
Time Frame: At 12 and 24 weeks
|
DCR at 12 and 24 weeks is defined as the percentage of participants who have a Complete response (CR) or Partial response (PR) in the first 13 and 25 weeks or who have Stable disease (SD) for at least 11 and 23 weeks after the date of first dose respectively, per RECIST 1.1 as assessed by the investigator at local site and derived from the raw tumour data.
|
At 12 and 24 weeks
|
Progression free survival (PFS)
Time Frame: Through study completion, an average of 2 years
|
PFS is defined as the time from the start of study intervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression, whichever occurs first.
|
Through study completion, an average of 2 years
|
Overall Survival (OS)
Time Frame: Through study completion, an average of 2 years
|
OS is defined as the time from the start of study intervention until the date of death due to any cause, whichever occurs first.
|
Through study completion, an average of 2 years
|
Anti Drug Antibody (ADA)
Time Frame: Through study completion, an average of 2 years
|
Incidences of ADAs against novel immunomodulators in serum.
|
Through study completion, an average of 2 years
|
Pharmacokinetics of novel immunomodulators: Maximum plasma concentration of the study drug (Cmax)
Time Frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )
|
Maximum observed plasma concentration of the study drug
|
From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )
|
Pharmacokinetics of novel immunomodulators: Time to maximum plasma concentration of the study drug (T-max)
Time Frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )
|
Time to maximum observed plasma concentration of the study drug
|
From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years )
|
lmmunogenicity of novel immunomodulators
Time Frame: From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years)
|
The number and percentage of participants who develop ADAs.
|
From the first dose of study intervention, at predefined intervals throughout the administration of novel immunomodulators ( approx 2 years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Biliary Tract Diseases
- Carcinoma, Hepatocellular
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Bevacizumab
- Lenvatinib
- Gemcitabine
Other Study ID Numbers
- D7987C00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States